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Chronic stress in mice remodels lymph vasculature
to promote tumour cell dissemination
Caroline P. Le1, Cameron J. Nowell1, Corina Kim-Fuchs1,2, Edoardo Botteri3, Jonathan G. Hiller4, Hilmy Ismail4,
Matthew A. Pimentel1, Ming G. Chai1, Tara Karnezis5,6, Nicole Rotmensz3, Giuseppe Renne7, Sara Gandini3,
Colin W. Pouton8, Davide Ferrari9, Andreas Mo¨ller10, Steven A. Stacker5,6 & Erica K. Sloan1,4,11,12,13,14
Chronic stress induces signalling from the sympathetic nervous system (SNS) and drives
cancer progression, although the pathways of tumour cell dissemination are unclear. Here we
show that chronic stress restructures lymphatic networks within and around tumours to
provide pathways for tumour cell escape. We show that VEGFC derived from tumour cells is
required for stress to induce lymphatic remodelling and that this depends on COX2
inﬂammatory signalling from macrophages. Pharmacological inhibition of SNS signalling
blocks the effect of chronic stress on lymphatic remodelling in vivo and reduces lymphatic
metastasis in preclinical cancer models and in patients with breast cancer. These ﬁndings
reveal unanticipated communication between stress-induced neural signalling and inﬂam-
mation, which regulates tumour lymphatic architecture and lymphogenous tumour cell
dissemination. These ﬁndings suggest that limiting the effects of SNS signalling to prevent
tumour cell dissemination through lymphatic routes may provide a strategy to improve cancer
outcomes.
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I
n everyday life, we encounter stressful experiences that pose a
threat to physiological homeostasis. These threats trigger stress
responses, including activation of the sympathetic nervous
system (SNS), which leads to elevated local and systemic levels of
catecholaminergic neurotransmitters that signal to cells1. Stress-
induced SNS signalling is important to enhance alertness and
physiological functions for rapid reaction to threat2. However,
chronic periods of stress can be detrimental to health by
increasing inﬂammation and promoting the progression of
diseases including cancer3–6. Clinical studies have linked
experience of stressful events to poor cancer survival7,8. This is
supported by preclinical studies that show chronic stress
promotes cancer progression3,4,6. These studies found that
stress recruits inﬂammatory cells to tumours and increases the
formation of blood vessels3,6, which may provide routes for
tumour cell dissemination. In addition to dissemination through
blood vessels, cancer cells also escape from tumours through
lymphatic vasculature9–11.
The lymphatic system plays an important role in immune
function and therefore can inﬂuence the trajectory of disease
progression. Under normal physiological conditions, the lym-
phatic system maintains homeostasis by directing cells and
solutes from the interstitial ﬂuid of peripheral tissues through
lymphatic vessels and into lymph nodes, where they undergo
immune examination12,13. In addition, the lymphatic system aids
in the resolution of inﬂammation by transporting immune cells
away from sites of infection14. In cancer, the lymphatic system
contributes to disease progression by providing a pathway for
tumour cell escape while also being a rich source of chemokines
that can promote the invasive properties of tumour cells15.
Furthermore, tumour-draining lymph nodes and associated
lymphatic endothelium have been shown to develop an
immunosuppressive environment, which promotes immune
tolerance to the cancer and facilitates tumour growth and
spread16–18. The importance of the lymphatic system in cancer
progression is supported by vast clinical data that show tumour-
associated lymphatic vessel density (LVD), tumour cell invasion
into lymphatic vasculature and the presence of tumour cells in
lymph nodes are each associated with increased clinical tumour
stage and reduced disease-free survival19–21.
The lymphatic system is innervated by ﬁbres of the SNS22, and
acute SNS activity has been shown to increase lymphatic vessel
contraction23,24 and lymphocyte output into lymphatic
circulation25. However, little is known about whether stress-
induced SNS signalling affects tumour lymphatic vasculature and
the consequences this may have on cancer progression.
In this study, we show that chronic stress increases intra-
tumoural LVD while also inducing dilation and increasing ﬂow in
lymphatic vessels that drain metastatic tumour cells into
lymphatic circulation. Inhibition of COX2 activity blocked the
effect of stress on lymphatic vascular remodelling, and showed a
key role for macrophage-mediated inﬂammation in the effects of
stress. In addition, we show a critical role for tumour cell-derived
VEGFC in the effects of stress on lymphatic vasculature. In both
clinical and preclinical studies we demonstrate that disrupting
SNS regulation of lymphatics, by blocking b-adrenoceptor
signalling, protects against lymphatic dissemination and cancer
progression. These ﬁndings identify stress signalling as a regulator
of lymphatic remodelling and provide evidence for the feasibility
of clinically targeting SNS regulation of lymphatics to prevent
tumour cell dissemination through lymphatic routes.
Results
Chronic stress remodels tumour lymphatic vasculature.
Stress-related psychosocial factors have been linked to increased
cancer-related mortality8. This is supported by accumulating
preclinical data that show chronic stress acts through SNS
signalling to promote progression of multiple tumour types3,4,6,26.
However, the role of the lymphatic system in stress-induced
tumour cell dissemination is unknown. To examine the effect of
stress on tumour-associated lymphatics, we used an orthotopic
model of breast cancer in which primary tumours were developed
from MDA-MB-231 human breast cancer cells. Mice were
subjected to a well-established chronic stress paradigm that
activates SNS signalling whereby inescapable conﬁnement
induces escape-avoidance behaviour (Fig. 1a). This paradigm
has been shown to elevate stress hormones without activating
motor-sensory pain pathways3. To examine the effect of
stress on intratumoural lymphatic vasculature, we used
immunohistochemical analysis to quantify the expression of the
lymphatic endothelial cell marker LYVE-1 (ref. 27) within
primary tumour sections as a measure of tumour LVD.
Multiple ﬁelds of view were captured around the periphery of
the tumour margin (Supplementary Fig. 1A). Chronic stress
signiﬁcantly increased tumour LYVE-1 staining compared with
control tumour-bearing mice (Fig. 1b), demonstrating that
stress-induced SNS signalling can increase the lymphatic
network within primary tumours. Consistent with our previous
ﬁndings, chronic stress did not affect primary tumour growth
(Fig. 1c and Supplementary Fig. 1B), conﬁrming that the effect of
stress on LVD was independent of primary tumour size.
Stress similarly increased tumour LVD in immunocompetent
BALB/c mice with 66cl4 luminal B mammary tumours
(Supplementary Fig. 1C) demonstrating that stress induces
lymphatic remodelling in a model with an intact immune system.
Our previous studies found that dilation of lymphatic vessels
that drain primary tumours increase metastasis to lymph node28.
We showed that lymph vessel dilation was dependent on
inﬂammatory signalling, but the physiological conditions in
which collector dilation increases metastasis remain unclear29.
Therefore, we sought to evaluate if, in addition to increasing
intratumoural LVD, chronic stress could also change the diameter
of lymphatic vessels that drain primary tumours. We used the
clinical lymph-tracing agent Patent Blue V dye30 to track lymph
drainage from the primary tumour and to quantify the diameter
of tumour-draining lymphatic vessels28. Comparisons between
the lymphatic vessels of control versus stressed mice revealed that
chronic stress caused signiﬁcant dilation of the lymphatic vessel
that drains the primary tumour (Fig. 1d). This effect was
independent of changes in the diameter of the adjacent blood
vessel (Supplementary Fig. 1D) and was maintained even 2 weeks
after the cessation of stress, showing that stress induces stable
changes in tumour-associated lymphatic architecture. These data
demonstrate the ability of chronic stress signalling to not only
increase the density of lymphatic vessels within the primary
tumour but also to induce stable dilation of the lymphatic vessels
that drain primary tumours, suggesting an increased capacity for
tumour cell dissemination.
As the functionality of intratumoural lymphatics has been
debated31,32, we ﬁrst examined if tumour-associated lymphatic
vessels are viable routes for tumour cell dissemination.
Immunohistochemical analysis of primary mammary tumours
identiﬁed cell emboli within the lumen of intratumoural
lymphatic vessels that stained positive for LYVE-1
(Supplementary Fig. 1E). Furthermore, we show that the
tumour-associated lymphatic vasculature in this model is
functional as it drained Patent Blue V dye from the tumour
(Fig. 1d,e). To investigate if tumour cells spontaneously
disseminate from orthotopic mammary tumours into lymphatic
vasculature, we developed methodology to directly visualize
tumour cells in these tumour-draining lymphatic vessels in live
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animals. MDA-MB-231 tumour cells were tagged with the
mCherry ﬂuorescent marker and implanted into the fourth
mammary fat pad (Fig. 1e, left panel). Once tumours reached
150mm3, ﬂuorescently tagged nanospheres were injected into the
inguinal lymph node, and intravital multiphoton ﬂuorescence
microscopy was used to visualize the nanospheres ﬂowing
through the draining lymphatic vessel in situ (Fig. 1e, right
panels). We detected mCherryþ tumour cells that had
spontaneously intravasated from the primary tumour along the
length of the draining lymphatic vessel towards the tumour-
draining lymph node (Fig. 1e, Supplementary Fig. 1F and
Supplementary Movie 1).
Having demonstrated that lymphatic vasculature is indeed a
route for spontaneous tumour cell dissemination in this model,
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we then sought to determine whether these stress-induced
alterations in lymphatic architecture were associated with
increased tumour cell dissemination to lymphatic organs. We
used MDA-MB-231 cells tagged with ﬁreﬂy luciferase for
longitudinal in vivo optical bioluminescence imaging to monitor
cancer progression (Fig. 1f). Consistent with tumour LVD and
lymphatic vessel dilation having a key role in lymphogenous
tumour cell dissemination28, stress-induced changes in lymphatic
architecture were associated with increased metastasis to lymph
nodes (Fig. 1g). Chronic stress also accelerated initial signs of
metastasis, which were observed as early as 11 days post tumour
cell injection (Fig. 1h and Supplementary Fig. 1G). The presence
of tumour cells in the tumour-draining lymphatic vessel was
associated with increased lymph node metastasis (Fig. 1i), and
there was a shift to higher frequency of tumour-positive lymph
nodes with stress (Supplementary Fig. 1H and Supplementary
Table 2). Consistent with clinical observations that lymph node
involvement is prognostic for distant metastasis, tumour cell
dissemination to lymph nodes was associated with increased
distant metastasis to lung (Fig. 1g). Chronic stress similarly
increased tumour cell dissemination to lymph nodes in
immunocompetent BALB/c mice with 66cl4 mouse mammary
tumours33 and in mouse mammary tumour virus-polyoma
middle T oncoprotein (MMTV-PyMT) transgenic mice that
spontaneously develop mammary tumours and metastasis
(Fig. 1j,k)34. These ﬁndings identify chronic stress as a
regulator of tumour-associated lymphatics and demonstrate that
stress-induced changes in lymphatic architecture are functional
and provide pathways for tumour cell dissemination to increase
lymph node metastasis. While these ﬁndings do not exclude that
stress also increases metastasis by promoting haematogenous
routes of dissemination3,6, they raise the possibility that targeting
stress signalling to modulate lymphatic vasculature may limit
lymphatic avenues of tumour cell dissemination.
SNS signalling can be leveraged to regulate lymph ﬂow.
Innervation of the lymphatic system by ﬁbres of the SNS provides
evidence for a direct link between the stress-activated SNS and
lymphatic function. This raises the possibility that SNS signalling
could increase lymph ﬂow and facilitate tumour cell dissemina-
tion. Using multiphoton microscopy, we ﬁrst conﬁrmed that
lymph nodes are innervated with catecholaminergic THþ ﬁbres
of the SNS (Supplementary Fig. 2A). To investigate if the SNS
could be acutely targeted to modulate lymphatic function, we
examined the effect of neuraxial anaesthesia on lymph ﬂow
in a clinical setting. Some anaesthetic agents, such as
neuraxial anaesthesia, inhibit nerve signalling, which results in
sympathectomy in the area of associated sensory blockade35.
Therefore, to investigate whether acute inhibition of sympathetic
signalling could reduce lymph ﬂow, we conducted a proof-of-
concept study using nuclear lymphoscintigraphy to track the
effect of neuraxial anaesthesia on lymph ﬂow in the lower limbs
of a consenting patient receiving brachytherapy for cervical
carcinoma. Unlike most patients receiving spinal anaesthesia,
patients receiving brachytherapy have no surgery-induced
lower limb wound oedema that would otherwise confound
interpretation of the study’s ﬁndings. Regional sympathetic
blockade was induced by the administration of intrathecal
ropivicaine at L3/4. Nuclear lymphoscintigraphy was used to
track lymph drainage of a radiolabelled tracer (Technetium-99m
antimony sulphide colloid, 99mTc-ASC) from the injection site in
the feet through lymph vasculature to lymph nodes in the pelvis
(Fig. 2a). To minimize confounding of anatomical variation,
lymph ﬂow was assessed before and after the implementation of
SNS blockade in the same individual. To minimize the potential
contribution of blood pressure, heart rate or muscle contraction
to changes in lymph drainage, the patient remained stationary in
a supine position for the duration of the study, and
lymphoscintigraphy only commenced after blood pressure was
stabilized. Under baseline conditions, tracer activity at the site of
injection in the feet decreased over time and accumulated in
pelvic lymph nodes, indicating clearance of the tracer by
lymphatic ﬂow (Fig. 2b,c). In contrast, sympathetic blockade
reduced outﬂow of the tracer from feet by 84% and inﬂow to
pelvic lymph nodes by 80% after 60min, demonstrating that SNS
signalling is necessary for lymph ﬂow and that clinical strategies
may be used to modulate SNS signalling and block lymph
function.
Having shown that acutely blocking SNS signalling blocks
lymph ﬂow, we then investigated if conversely activating SNS
signalling was sufﬁcient to increase lymph ﬂow. Activation of the
SNS leads to the release of the endogenous neurotransmitter
norepinephrine from local SNS ﬁbres1. To mimic the local
release of norepinephrine from tissue nerve endings,
norepinephrine was administered intravenously to directly
activate SNS signalling pathways, and lymph ﬂow was
measured using intravital multiphoton microscopy to track the
rate of transit of ﬂuorescent nanospheres through lymphatic
vessels of anaesthetized mice. Nanospheres were injected into the
inguinal lymph node and the baseline rate of ﬂow of nanospheres
through the draining efferent lymphatic vessel was quantiﬁed
after 3min had elapsed to allow ﬂow to stabilize. Recording from
lymphatic vessels was conﬁrmed by the presence of occasional
valves (Fig. 2d). Treatment with a single dose of norepinephrine
signiﬁcantly elevated the rate of lymph ﬂow through collecting
Figure 1 | Chronic stress remodels tumour-associated lymphatic architecture to promote lymph node metastasis. (a) Schematic representation of the
chronic stress paradigm. (b) Quantiﬁcation and representative images of tumour LVD (LYVE-1þ , green; nuclear, blue) immunostaining of MDA-MB-231
orthotopic tumours. Scale bar, 200mm (n¼ 5). (c) Quantiﬁcation of MDA-MB-231 primary tumour size in control or stressed BALB/c nu/numice over time
(n¼ 5 at each time point). (d) Quantiﬁcation and representative images of tumour-draining lymphatic vessel diameter (LV, blue) in mice with MDA-MB-
231 tumours. Scale bar, 1mm (nZ7). (e) Left: skin ﬂap preparation after injection of Patent Blue V dye into the primary tumour (PT) showing the dye taken
up into the tumour-draining LV and into the tumour-draining axillary lymph node (AxLN). The LV is adjacent to a blood vessel (BV). Right top panel:
epiﬂuorescence image of mCherry-tagged MDA-MB-231 tumour cells (TCs, red) that had spontaneously disseminated from orthotopic PT and were
present in the tumour-draining LV that contained microspheres (green) and was adjacent to an autoﬂuorescent BV. Right lower panel: corresponding
maximum projection of multiphoton image. Scale bar, 100mm (Supplementary Movie 1). (f) Representative in vivo bioluminescence image of orthotopic
MDA-MB-231 breast cancer model showing PT, and spontaneous metastasis to draining lymph node (LN) and lung 21 days after tumour cell injection.
(g) Representative images of LN and lung metastasis and quantiﬁcation of metastasis by ex vivo bioluminescence (BLI) imaging in control versus stressed
mice with MDA-MB-231 tumours (n¼ 5). (h) Metastasis in vivo over time (n¼ 5 at each time point). (i) LN metastasis in mice that were negative or
positive for tumour cells in collecting lymphatic vessels (nZ13). (j) Ex vivo quantiﬁcation of bioluminescence from LN at day 28 of 66cl4 tumour
progression from control or stressed mice (n¼ 5). (k) Area of lymph node metastasis when primary tumour diameter reached 12mm in control or stressed
MMTV-PyMT mice (nZ8). Experiments were completed 2–4 times. All data represent mean±s.e. **Po0.01 and ***Po0.001 by Student’s t-test or
Mann–Whitney U-test (post hoc Bonferroni correction).
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lymphatic vessels in mice (Fig. 2e,f and Supplementary Movie 2)
demonstrating the ability of acute SNS signalling to promote
lymphatic ﬂow. The baseline rate of lymph ﬂow in the absence of
norepinephrine treatment was observed to vary considerably
between animals (Supplementary Fig. 2B), consistent with
previous data36. Therefore, as with the clinical lymph ﬂow
studies, measurements were taken in each mouse before and after
norepinephrine administration. Together, these ﬁndings indicate
that SNS signalling is a potent regulator of lymph ﬂow and that
existing clinical strategies may be utilized to selectively alter
lymph function.
b-adrenergic signalling remodels tumour lymphatic vessels.
Norepinephrine is released from parenchymal nerve ﬁbres in
response to stress, and binds b-adrenoceptors to modulate cell
function1. b-adrenoceptors are present on tumour cells and
stromal cell populations in the tumour microenvironment37,38,
including inﬂammatory cells6. Accumulating evidence from
preclinical studies suggests that chronic stress promotes cancer
progression through b-adrenoceptor activation3,4,6,26,39. To
investigate if b-adrenergic signalling is required for the
effects of stress on intratumoural LVD, we treated mice
with propranolol, a non-selective b-adrenoceptor antagonist
(beta-blocker; BB) that is used clinically for the treatment of
hypertension. Treatment with propranolol during MDA-MB-231
tumour development blocked chronic stress from increasing
tumour LYVE-1þ LVD and reduced metastasis to lymph nodes,
suggesting that reduced LVD had functional effects on tumour
cell dissemination (Fig. 3a and Supplementary Table 1).
Conversely, systemic activation of b-adrenoceptors with the
b-adrenoceptor agonist isoproterenol was sufﬁcient to increase
intratumoural LVD and increase lymph node metastasis (Fig. 3b
and Supplementary Fig. 3A) without affecting primary tumour
growth (Supplementary Fig. 3B). These ﬁndings demonstrate that
b-adrenoceptor signalling is sufﬁcient to promote intratumoural
LVD and is necessary for the adverse effects of stress on
lymphatic vascular remodelling.
VEGFC mediates stress-induced lymphatic remodelling. To
deﬁne the molecular mechanisms that drive stress-induced
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changes in lymphatic vasculature, we used quantitative reverse
transcription–PCR (qRT–PCR) to proﬁle the effect of stress on
the expression of vascular endothelial growth factors (VEGFs).
VEGFA, VEGFC and VEGFD are central to lymphangiogenesis,
and their expression in tumours is associated with poor cancer
outcome21,40–42. Using species-speciﬁc probes (Supplementary
Fig. 4A), we found that chronic stress elevates the expression of
both tumour cell-derived and stromal cell-derived VEGFC in
MDA-MB-231 primary tumours (Fig. 4a). SNS regulation of
VEGFC expression was also conﬁrmed in 66cl4 mammary
tumours from immunocompetent mice or in mammary
tumours from MMTV-PyMT transgenic mice (Fig. 4b). VEGFC
has been shown to promote tumour lymphangiogenesis and
metastasis to lymph nodes in preclinical cancer models43,44, and
is associated with increased lymph node metastasis and decreased
progression-free survival in patients40. Treatment with
isoproterenol also elevated tumour cell and stromal cell VEGFC
expression (Supplementary Fig. 4B), while BB treatment blocked
the effect of stress on VEGFC expression (Fig. 4c), demon-
strating the importance of b-adrenoceptor activation in
stress-induced expression of this lymphangiogenic factor.
VEGFC binds to its receptor VEGFR3 (FLT4) to drive tumour
lymphangiogenesis43,45–47. Chronic stress or treatment with
isoproterenol also increased stromal cell expression of Vegfr3
(Fig. 4d and Supplementary Fig. 4C), indicating that
b-adrenoceptor signalling increases the capacity for VEGFC–
VEGFR3 signalling.
To investigate the contribution of tumour cell-derived
VEGFC in SNS-induced lymphatic remodelling, we used
short hairpin RNA to stably silence VEGFC in MDA-MB-231
tumour cells (Supplementary Fig. 4D). Knockdown of
VEGFC blocked stress-induced LYVE-1þ LVD in primary
tumours (Supplementary Fig. 4E), demonstrating a key
role for tumour cell VEGFC in stress-induced lymphatic
remodelling. VEGFC knockdown also blocked the ability of
stress to promote lymphogenous metastasis and distant
metastasis (Fig. 4e), consistent with a critical role for VEGFC-
dependent lymphangiogenesis in stress-enhanced tumour cell
dissemination. These data demonstrate that tumour cell-derived
VEGFC is necessary for stress-induced lymphatic remodelling
and metastasis.
To begin to investigate possible stromal sources of VEGFC,
we treated lymphatic endothelial cells (LECs) and primary
macrophages—both of which express b-adrenoceptors
(Supplementary Fig. 4F)6,48—with isoproterenol. b-agonism
increased Vegfc expression in macrophages but not in LECs
(Fig. 4f). However, stress did not elevate Vegfc expression in
CD11bþF4/80þ macrophages isolated from primary mammary
tumours (Fig. 4g), suggesting that there may be additional
stromal sources of stress-regulated VEGFC.
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Stress remodels tumour lymphatics via inﬂammation. While
chronic stress increased tumour cell VEGFC expression in
primary mammary tumours in vivo (Fig. 4a), direct treatment
of cultured tumour cells with the b-adrenoceptor agonist iso-
proterenol was insufﬁcient to drive VEGFC expression in vitro
(Fig. 4f), suggesting that a mediating factor is required for the
effect of stress on tumour cell VEGFC expression in vivo. As
inﬂammation promotes VEGFC expression and drives lymphatic
remodelling15, we investigated if inﬂammatory pathways are
linked to stress regulation of lymphatic vasculature in vivo. We
ﬁrst looked at expression of the inﬂammatory marker
cyclooxygenase-2 (COX2, or PTGS2). While tumour COX2
levels were low in control mice, stress or isoproterenol elevated
COX2 mRNA transcript levels (Fig. 5a and Supplementary
Fig. 5A), which were strongly associated with VEGFC mRNA
levels (Fig. 5b and Supplementary Fig. 5B). This is consistent with
ﬁndings in other solid cancers49–52, and extends observations that
inﬂammation is linked with lymph vessel formation by
identifying stress signalling as a potential driver of this
relationship. To determine if inﬂammation is necessary for stress
to modulate lymphatic architecture and lymphogenous spread, we
treated control and stressed mice bearing MDA-MB-231
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mammary tumours with the COX2 inhibitor celecoxib. Inhibition
of COX2 activity blocked the effect of stress on tumour LYVE-1þ
LVD (Fig. 5c,d) and prevented metastasis to lymph node and
distant organs (Fig. 5c,d and Supplementary Fig. 5C),
demonstrating a functional consequence of limiting lymphatic
remodelling.
Prostaglandin E2 (PGE2) is a well-characterized inﬂammatory
eicosanoid produced by COX2. To investigate if PGE2 may
induce VEGFC in tumour cells, we treated MDA-MB-231 cells
with PGE2. We found a concentration-dependent increase in
tumour cell VEGFC expression and protein secretion (Fig. 5e
and Supplementary Fig. 5D), suggesting the COX2-PGE2
inﬂammatory pathway as a plausible mediator of stress-induced
lymphatic remodelling. Macrophages are a key source of
inﬂammatory molecules in the tumour microenvironment53,54.
They are also highly sensitive to stress signalling, which
leads to their recruitment to primary mammary tumours6,55.
To investigate if b-adrenergic signalling regulates macrophage
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PGE2 production, we treated primary macrophages with
isoproterenol and assayed inﬂammatory mediators. Direct
activation of b-adrenoceptor signalling elevated COX2
expression and PGE2 production in primary bone marrow-
derived macrophages (Fig. 5f,g) and human monocyte-derived
macrophages (Supplementary Fig. 5E), while physiological
activation of b-adrenoceptor signalling by chronic stress
elevated COX2 expression in CD11bþF4/80þ macrophages
isolated from primary mammary tumours (Fig. 5h). These
ﬁndings conﬁrm that stress signalling can regulate the COX2-
PGE2 pathway in tumour-associated macrophages (TAMs). To
investigate if macrophages are necessary for the effects of stress
on intratumoural lymphatic remodelling, we treated mice with a
small molecule inhibitor of colony-stimulating factor 1 receptor
GW2580, which we have previously shown blocks stress-induced
macrophage recruitment to primary mammary tumours6.
Blocking macrophage recruitment prevented stress-induced
VEGFC expression in tumours and blocked lymphatic
dissemination as shown by reduced lymph node metastasis
(Fig. 5i). While not excluding other cellular sources of
prostaglandins56, these data suggest that TAMs may be one
source of the inﬂammatory signalling required for stress-
enhanced VEGFC expression and lymphogenous dissemination.
Clinical BB use is linked to reduced lymph node metastasis.
These ﬁndings suggest that targeting b-adrenergic stress-responsive
signalling may provide a clinical strategy to limit lymphogenous
tumour cell dissemination. Recent retrospective, epidemiological
studies have linked BB use to improved cancer outcomes57–60, but
it is unclear if lymphogenous dissemination was affected. We
therefore investigated the incidence of lymph node metastasis in a
cohort of 956 breast cancer patients during an average of 78
months after diagnosis (Table 1). Multivariate analysis revealed BB
use was signiﬁcantly associated with reduced risk of lymph node
metastasis (Fig. 6a), after controlling for age, tumour stage,
peritumoural vascular invasion, tumour treatment and other
cardiac medications (hazard ratio, 0.13; 95% conﬁdence interval,
0.02–0.97; P¼ 0.04 by Cox regression analysis; Table 2). During
the follow-up period, 47 lymph node metastases were identiﬁed in
patients not taking BB (5.5% of patients) versus only 1 lymph node
metastasis in patients taking BB (1.1%, P¼ 0.07 by Gray’s test;
Table 2). Consistent with our earlier analysis of a subset of these
patients60, BB use was also associated with decreased distant
metastasis (Fig. 6b). There was no association between BB use and
local recurrence (Fig. 6c), consistent with our in vivo studies that
found b-adrenoceptor signalling did not affect primary tumour size
or growth (Fig. 1c and Supplementary Fig. 1B).
Table 1 | Characteristics at baseline by BB intake.
Variable Category No BB no. (%) BB no. (%) P value
Total 863 (90.3) 93 (9.7)
Age Median (range) 60 (30–92) 63 (48–80) o0.01
o65 593 (68.7) 50 (53.8) o0.01
Z65 270 (31.3) 43 (46.2)
BMI o25 459 (59.8) 48 (53.9) 0.10
25–30 238 (31.0) 27 (30.3)
430 70 (9.1) 14 (15.7)
T* 1 387 (46.0) 51 (54.8) 0.23
2 340 (40.4) 31 (33.3)
3 42 (5.0) 4 (4.3)
4 72 (8.6) 7 (7.5)
N* 0 449 (54.4) 51 (56.0) 0.89
1 253 (30.7) 26 (28.6)
2/3 123 (14.9) 14 (15.4)
Ki-67 Median (range) 42 (1–95) 38 (4–90) 0.12
r40 408 (49.2) 53 (57.6) 0.12
440 422 (50.8) 39 (42.4)
Peritumoural vascular invasion Absent 650 (75.8) 73 (79.3) 0.39
Focal 110 (12.8) 11 (12.0)
Extensive 98 (11.4) 8 (8.7)
Neoadjuvant chemotherapy No 716 (83.0) 80 (86.0) 0.45
Yes 147 (17.0) 13 (14.0)
Type of surgery MAST 206 (23.9) 20 (21.5) 0.61
QUAD 657 (76.1) 73 (78.5)
Radiotherapy No 138 (16.0) 12 (12.9) 0.44
Yes 725 (84.0) 81 (87.1)
ACEI No use 763 (88.4) 68 (73.1) o0.01
Use 100 (11.6) 25 (26.9)
ARB No use 817 (94.7) 80 (86.0) o0.01
Use 46 (5.3) 13 (14.0)
CCB No use 808 (93.6) 79 (84.9) o0.01
Use 55 (6.4) 14 (15.1)
Diuretic No use 785 (91.0) 60 (64.5) o0.01
Use 78 (9.0) 33 (35.5)
Antithrombotics No use 837 (97.0) 83 (89.2) o0.01
Use 26 (3.0) 10 (10.8)
Statins No use 812 (94.1) 80 (86.0) o0.01
Use 51 (5.9) 13 (14.0)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; MAST, mastectomy; QUAD, quadrantectomy.
*Clinical stage was used for patients undergoing neoadjuvant chemotherapy. Numbers might not sum up to totals due to missing values. P values were obtained using w2-test or Fisher’s exact test, as
appropriate.
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Discussion
These ﬁndings identify chronic stress as a pathophysiological
regulator of lymphatic remodelling in cancer (Fig. 7). We
demonstrate that chronic stress induces stable changes in
intratumoural and peritumoural lymphatic architecture, and
increases lymphogenous tumour cell dissemination leading to
increased lymph node metastasis. These studies deﬁne a critical
role for neural-inﬂammatory signalling in the adverse effects of
stress on tumour lymphatic remodelling. Additionally, the
ﬁndings show that stress-induced vascular remodelling is
dependent on b-adrenergic signalling to inﬂammatory cells,
which increases tumour cell-derived VEGFC. Furthermore, we
demonstrate the translational potential of these ﬁndings by
showing that stress-induced SNS signalling may be blocked
pharmacologically to prevent lymph vascular remodelling, to
reduce lymph ﬂow and to prevent tumour cell dissemination.
These ﬁndings expand our understanding of the role of
lymphogenous dissemination in metastasis by identifying chronic
stress as an external factor that drives lymphogenous spread.
Lymphatic dissemination has been described as a passive process
that presents the lowest barrier to tumour cell escape and
survival61. Rather than being passive, we show that lymphatic
dissemination may be directed by external (non-tumour)
inﬂuences. Speciﬁcally, we show that chronic stress drives SNS
signalling to form new lymphatic pathways of tumour cell escape.
We show that SNS signalling increases ﬂow through lymphatic
vessels, which could potentially increase tumour cell
dissemination. In addition, it has been suggested that increased
lymph ﬂow promotes immune tolerance of tumour antigens
through a VEGFC-centric mechanism62, suggesting an alternate
mechanism by which stress may promote metastatic escape by
modulating the immune system. The importance of lymphatic
dissemination in metastatic progression has been questioned due
to the ability of distant metastasis to form seemingly in the
absence of functional lymphatics32. Our studies using Patent
Blue V drainage and intravital microscopy provide evidence
for functional tumour-associated lymphatic vasculature and
spontaneous tumour cell dissemination from orthotopic
mammary tumours.
It will be important to deﬁne stromal sources of VEGFC
(Fig. 4a). Macrophages are a known source of VEGFC43, and
treatment with isoproterenol increases Vegfc expression in
primary bone marrow-derived macrophages (Fig. 4f). However,
we found no evidence that stress increased VEGFC expression by
TAMs (Fig. 4g). This suggests that while macrophages may act
through an autocrine mechanism to increase macrophage
VEGFC synthesis, this may not be the main source of stromal
VEGFC in tumours of stressed individuals. While it is also
plausible that LECs and ﬁbroblasts may be additional sources of
prostaglandins56, we found that direct b-adrenergic signalling
to LECs did not modulate PGE2 production in vitro
(or VEGFC expression) (Fig. 4f and Supplementary Fig. 5E). In
contrast, the data presented here suggest that PGE2 derived from
TAMs may contribute to stress regulation of tumour cell-derived
VEGFC. In addition, it will be important to deﬁne the direct effect
of stress on lymphatic vasculature function, as isolated lymphatic
vessels have been shown to respond to b-agonists63. Further
studies using strategies such as cell-speciﬁc knockout will be
required to assess the effect of b-adrenergic signalling on these
various cell populations and determine their respective
contributions to remodelling of lymphatic vasculature.
Our ﬁnding that BB treatment prevents lymphatic remodelling
and tumour cell dissemination, provides new mechanistic insight
to explain recent clinical observations that BB use is associated
with reduced metastasis and improved survival57–60. b-adrenergic
regulation of lymphogenous tumour cell dissemination—with no
effect on primary tumour growth—may explain why clinical BB
use was not associated with primary tumour recurrence. Our
ﬁnding that SNS signalling may be acutely leveraged to limit
lymph ﬂow suggests that the perioperative period may be an
additional opportunity for interventions that target stress
signalling. Selective choice of anaesthetic agents that block SNS
signalling and lymph ﬂow may help to limit dissemination of
tumour cells that become displaced from the tumour during
surgical resection. While the capacity of anaesthetic
sympathectomy to limit tumour cell dissemination or
perioperative inﬂammation is still unclear, the use of SNS-
blocking neuraxial anaesthesia has been associated with improved
cancer outcomes64.
These ﬁndings suggest that it may be important to identify
stressed individuals who may be particularly susceptible to
lymphogenous dissemination. One approach may be through
transcriptional proﬁling using a stress signature55. Alternatively,
as cancer is often a highly stressful experience, it is plausible that
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Figure 6 | BB use is associated with reduced lymph node and distant
metastasis. Cumulative incidence of (a) lymph node metastasis, (b) distant
metastasis and (c) primary tumour recurrence by BB use in patients with
triple-negative breast cancer (n¼ 863, no BB; n¼93, BB). HR, adjusted
hazard ratio (95% conﬁdence interval). P values calculated by Cox
regression.
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SNS intervention may be generally useful to improve cancer
outcome. In support of that contention, we found here that
clinical BB use was linked to a signiﬁcant reduction in lymph
node metastasis (and reduced distant metastasis) in a cancer
cohort without prior evaluation of stress levels.
Stress regulation of lymphatic vasculature may have evolved to
promote survival during times of threat. Co-ordinated regulation
of the ﬁght-or-ﬂight stress response with increased lymphatic
function may have provided an evolutionary advantage by
enhancing immune surveillance and activating a rapid immune
response to physical threat. However, the ﬁndings presented here
demonstrate that SNS-regulated lymphatic function can have
adverse effects in the context of chronic diseases such as cancer.
Importantly, these ﬁndings identify multiple points of clinical
intervention to limit these adverse effects of stress.
Methods
Cells. A highly metastatic variant of the MDA-MB-231 triple-negative breast
adenocarcinoma cell line (MDA-MB-231HM, a kind gift from Dr Zhou Ou, Fudan
University Shanghai Cancer Center, China) was transduced with a lentiviral vector
containing codon-optimized ﬁreﬂy luciferase-eGFP or -mCherry under the control
of the ubiquitin-C promoter as previously described65, and was cultured in DMEM
medium (Invitrogen) containing 10% fetal bovine serum (FBS) and 200mM
glutamine. The identity of this cell line was conﬁrmed by karyotyping (Cellbank,
Australia). Luminal B 66cl4 mammary adenocarcinoma cell line (a kind gift from
Prof. Robin Anderson, Peter MacCallum Cancer Centre, Australia) was transduced
with FUhlucW construct as previously described6, and cultured in a-MEM
medium (Invitrogen) containing 10% FBS and 200mM glutamine. Primary mouse
macrophages were derived from bone marrow of BALB/c nu/nu mice. Bone
marrow was isolated from mouse femurs and then cultured in RPMI medium
(Invitrogen) containing 10% FBS, 200 nM glutamine and 100 ngml 1 of CSF-1
(Sigma) for 7 days for macrophage maturation. Human monocyte cell line U937
(American Type Culture Collection)66 was cultured in RPMI medium (Invitrogen)
containing 10% FBS and 200 nM glutamine. To induce differentiation into
macrophages, U937 cells were treated with phorbol 12-myristate 13-acetate
(200 nM, Sigma) for 24 h. Human lymphatic endothelial cells (human dermal
microvascular endothelial cells; HMVEC-D, catalogue #: CC-2812, Lonza) were
cultured in EGM-2MV BulletKit supplemented with 5% FBS (Lonza). All cells were
maintained at 37 C and 5% CO2. VEGFC was silenced in MDA-MB-231 cells by
stable expression of short hairpin RNA against VEGFC (TRCN0000058503,
Mission Viral Particles, Sigma). Cells were transduced with viral particles
(multiplicity of infection 2) for 5 h and selected with puromycin (8 mgml 1;
Invitrogen). Single-cell clones were established from GFPþ sorted cells, and
knockdown of mRNA and protein levels were conﬁrmed by qRT–PCR and ELISA
(R&D Systems), respectively (Supplementary Fig. 4D). All cells were conﬁrmed
negative for mycoplasma contamination before use using the MycoAlert
Mycoplasma Detection Kit (Lonza).
Breast cancer models. For orthotopic tumour studies, 2 105 MDA-MB-231
cells or 1 105 66cl4 cells in 20ml PBS (Invitrogen) were injected into the fourth
mammary fat pad of anaesthetized (3% isoﬂurane) 8-week-old, female BALB/c nu/
nu (University of Adelaide, Australia) or BALB/cJAsmu (Monash Animal Research
Platform, Australia) mice, respectively. Mice were housed under PC2 barrier
conditions on 12 h dark/light cycle. Primary tumours were measured by caliper,
and volume was calculated by the formula: (lengthwidth2)/2. Metastasis was
tracked with bioluminescence using an IVIS Lumina II (Perkin Elmer) imaging
system by measuring luciferase activity (60-s exposure) after a tail-vein injection of
150mg kg 1 D-luciferin (CHOICE Analytical). After 22 (MDA-MB-231) or 29
(66cl4) days of tumour progression, mice were killed for evaluation. Tissue-speciﬁc
metastasis in lung, liver and lymph nodes were imaged ex vivo and frozen in
liquid nitrogen for immunohistochemistry and gene expression studies. For the
spontaneous metastasis model, 7-week-old female MMTV-PyMT-C57Bl/6 mice34
were used and metastasis evaluated by histology. CD11bþF4/80þ TAMs were
isolated from 66cl4 mammary tumours by ﬂuorescence-activated cell sorting.
Primary tumours were dissociated using collagenase type IV (Gibco) and stained
with ﬂuorescent-conjugated antibodies against CD11b (BD Biosciences, clone M1/
70, 1:200) and F4/80 (eBioscience, Clone BM8, 1:200). Sample sizes were
determined using conservative sample size calculations under a mixed-effect
Table 2 | Events and follow-up by BB intake.
Event No BB no. (%) BB no. (%) P value* HR (95% CI)w P valuew
At risk 863 93
First events
Lymph node metastasis 47 (5.5) 1 (1.1) 0.07 0.13 (0.02–0.97) 0.04
Distant metastasis 131 (15.2) 6 (6.5) 0.04 0.40 (0.17–0.93) 0.03
Local recurrence 68 (7.9) 6 (6.5) 0.74 0.93 (0.39–2.25) 0.93
Local or regional or distant 246 (28.5) 13 (14.0) o0.01 0.48 (0.25–0.79) o0.01
Overall mortality
Death from breast cancer 161 (18.9) 8 (8.6) 0.03 0.48 (0.23–0.99) 0.05
Death from other or missing causes 48 (5.6) 10 (10.8) 0.02 1.75 (0.84–3.62) 0.13
Follow-up
Months, median (Q1–Q3) 78 (46–109) 77 (47–105) 0.91
CI, conﬁdence interval; HR, hazard ratio; Q1, lower quartile; Q3, upper quartile.
*Univariate analysis: association between number of events and BB use was tested by the Gray test, while association between follow-up and BB use was tested by the median two-sample test.
wHRs and P values for testing BB versus non-BB were obtained using a Cox regression multivariable model that included age, tumour size, lymph node status, peritumoural vascular invasion, type of
surgery, radiotherapy, other cardiac medications and statins.
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Figure 7 | Stress-induced lymphatic remodelling. Stress remodels
lymphatic vasculature through a tumour neural-inﬂammatory axis to
promote lymphogenous tumour cell dissemination and metastasis. Tumour
cell-derived VEGFC is necessary for stress-enhanced lymphatic remodelling
but is not directly activated by b-adrenoceptor signalling. Tumour-
associated macrophages respond to b-adrenoceptor signalling to produce
inﬂammatory molecules such as PGE2, which may then signal to tumour
cells to produce VEGFC required for lymphatic remodelling. These effects
may be clinically blocked using BBs, anti-VEGFC therapeutics (aVEGFC) or
COX2 inhibitors (COX2i). E, epinephrine; NE, norepinephrine; b-AR,
b-adrenoceptor.
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longitudinal model with a power of 40.90 to detect a 5% change compared to
control at the 0.05 signiﬁcance level. All procedures were carried out under
protocols approved by the Monash Institute of Pharmaceutical Sciences Animal
Ethics Committee.
Chronic restraint stress. Female BALB/c nu/nu, BALB/cJAsmu or MMTV-
PyMT-C57Bl/6 mice at 8 weeks of age were randomly assigned to home cage
control conditions or chronic restraint stress (n¼ 5 per experimental group). Mice
were restrained in a conﬁned space that prevented them from moving freely
but did not press on them. These conditions increase tissue levels of the stress
neurotransmitter norepinephrine3. Mice were restrained for 2 h per day for 21 days
commencing 7 days before tumour cell inoculation or from 8 weeks of age for the
MMTV-PyMT model.
Pharmacologic studies. For b-agonist studies, 8-week-old female BALB/c nu/nu
mice received isoproterenol (Sigma; 5mg kg 1 day 1) by daily subcutaneous
injections for a total of 21 days. For BB studies, mice received propranolol (Sigma;
5mg kg 1 day 1) by mini-osmotic pump (Alzet, model 1004). For macrophage
inhibition studies, mice received GW2580 (R.I. Chemical; 160mg kg 1) as
previously described6. For COX2 inhibitor studies, mice received celecoxib
(Celebrex; Clifford Hallam; 25mg kg 1 day 1) in drinking water. Mice were
treated with inhibitors for the duration of the study.
Lymphangiography. A volume of 20ml of 0.25% (w/v) Patent Blue V dye (Sigma)
was injected intratumourally in anaesthetized 8-week-old female BALB/c nu/nu
mice for uptake into collecting lymphatic vessels as previously described28. A skin
ﬂap preparation was conducted by making an incision along the central line
separating the peritoneum from the skin containing lymphatic collectors.
Draining-collecting lymphatic vessels were imaged using a dissecting microscope
ﬁtted to an AxioCam ERc 5s camera (Zeiss). Average vessel diameter was
quantiﬁed acrossZ5 intervals using the Fiji distribution of ImageJ software (NIH)
by an investigator blinded to treatment conditions.
Immunohistochemistry. Following antigen retrieval with citrate buffer (0.01M,
pH 6), 5 mm cryosections of primary tumours or lymph nodes were ﬁxed with 4%
paraformaldehyde (Sigma) and then incubated with one or more primary
antibodies for 16 h at 4 C. Anti-LYVE-1 (Fitzgerald, catalogue #: 70R-LR003,
1:500) antibody was used to localize lymphatic vasculature followed by incubation
with corresponding Alexa-Fluor-conjugated secondary antibody (Invitrogen, cat-
alogue #: A31573, 1:500) and Hoechst 33342 nuclear staining (Sigma, catalogue #:
B2261, 1:1000). Immunostaining was visualized at  40 magniﬁcation using an
Eclipse 90i microscope (Nikon). LYVE-1þ LVD was evaluated in Z5 digital
images per sample captured at random intervals around primary tumour margins32
by an investigator blinded to treatment conditions. Area of vessel density
(percentage of total tissue area) was quantiﬁed using ImageJ software.
In vivo lymph ﬂow. Inert Fluoresbrite YG carboxylate nanospheres (50 nm;
Polysciences) at 0.025% in 10 ml PBS were injected into the left inguinal lymph
node of anaesthetized 8-week-old female BALB/c nu/nu mice. Visualization of
nanospheres was carried out using a Leica SP8 multiphoton as described
above. Emission was collected at 455/25 (second harmonic generation), 525/25
(nanospheres) and 585/20 nm (mCherry tumour cells). The baseline rate of ﬂow of
nanospheres through the efferent lymphatic vessel was quantiﬁed after 3min had
elapsed to allow ﬂow to stabilize. To investigate stress signalling in anaesthetized
mice, stress neurotransmitter norepinephrine (Sigma; 1mg kg 1) was injected
intravenously and impact on lymph ﬂow investigated. To avoid confounding of
anatomical variation, lymph ﬂow readings were taken in each mouse before and
after norepinephrine administration. Quantiﬁcation of lymphatic ﬂow rate was
carried out by manually tracking individual particles using the Fiji distribution of
ImageJ over Z10 time points. The average velocity of each particle was then
calculated in mms 1.
Nuclear lymphoscintigraphy. This proof-of-concept study involved comparing
lower limb lymphatic drainage under resting conditions with that following sym-
pathetic blockade in a consenting patient receiving brachytherapy for cervical
carcinoma (Project Number 09/15, Human Research Ethics Committee Peter
MacCallum Cancer Centre; ACTRN12612001162808). Written, informed consent
was obtained from the study subject. Regional sympathetic blockade was induced
by intrathecal ropivicaine administered at the L3/4 interspace. Conﬁrmation of
spinal anaesthesia was made before commencement of the lymphoscintigram using
ice testing to ensure a dermatome block higher than T9 (ref. 67). Unlike most
patients receiving spinal anaesthesia, patients receiving brachytherapy have no
surgery-induced lower limb wound oedema that would otherwise confound the
study’s results; patients with pre-existing alterations in lymphatic ﬂow or
sympathetic tone, chronic regional pain syndrome, lymphoedema, surgery or
trauma to the lower limbs, obesity (body mass index 430 kgm 2), diabetes
mellitus, patients receiving adrenergic receptor antagonists or anti-inﬂammatory
agents, and clinical pelvic or lower limb lymphadenopathy were excluded. To
minimize the confounding of anatomical variation, lymph ﬂow was assessed before
and after the implementation of sympathetic blockade in the same individual. In
alliance with common anaesthesia practice, intravenous ﬂuid resuscitation was
provided intraoperatively to the patient to achieve restoration of blood pressure
within 20% of starting blood pressure. 99mTc-ASC (0.25ml), a colloid that migrates
through the lymphatic vessels and is retained in the sentinel lymph node for 24 h
until cleared, was injected sub-dermally in the ﬁrst web-space of both feet, and
tracked from feet to inguinal lymph nodes using dynamic image acquisition over
60min (two head gamma camera, Philips Skylight).
Secreted protein quantiﬁcation. Cells were serum-starved overnight before
treatment with isoproterenol or PGE2 (Sigma). After 24 or 72 h conditioned
medium was centrifuged at 2,000 r.p.m. for 5min. Secreted levels of VEGFC or
PGE2 were quantiﬁed by ELISA according to the manufacturer’s instructions
(R&D Systems).
Messenger RNA isolation and qRT–PCR. qRT–PCR using TaqMan probes was
used to quantify VEGF (VEGFA; Hs00900055_m1), VEGFC (Hs01099203_m1),
FIGF (VEGFD; forward, 50-GTATGGACTCTCGCTCAGCAT-30 ; reverse, 50-
AGGCTCTCTTCATTGCAACAG-30), Ptgs2 (Cox2; Mm00478374_m1), PTGS2
(COX2; Hs00153133_m1), Flt4 (Vegfr3; Mm01292604_m1), FLT4 (VEGFR3;
Hs01047677_m1), Rpl30 (Mm01611464_g1) and RPL30 (Hs00265497_m1). Total
RNA was isolated from 2mm3 of mammary primary tumour tissue or 106 cultured
cells using RNeasy Mini Kit. A unit of 100 ng total RNA was assayed by qRT–PCR
reactions using standard PCR conditions through 60 PCR ampliﬁcation cycles and
normalized to human or mouse RPL30 housekeeping gene.
Clinical beta-blockade. A detailed description of a cohort of 800 triple-negative
breast cancer patients diagnosed and operated at the European Institute of
Oncology in Milan between 1997 and 2008 has been previously described60. For
this present study we added 2 years of observation (156 patients operated in the
same Institute between 2009 and 2010) and updated the entire cohort follow-up.
Use of the data, retrieved from the European Institute of Oncology Breast Cancer
Institutional Database, was approved by the European Institute of Oncology
Review Board. At the time of admission to the hospital, all patients gave their
consent for the use of their data for research purposes. Patients with history of any
previous invasive cancer or with metastatic disease at diagnosis (stage IV) were
previously excluded. Patients were divided into two groups: the BB users group,
which included patients who were using any BB at the time of cancer diagnosis;
and the BB non-users group, which included all other patients. Association
between the occurrence of ﬁrst metastatic events and BB use was evaluated in a
competing-risk survival analysis framework. Deﬁnition of events: local events are
recurrences in the ipsilateral breast. Lymph node events are events that involve the
axillary lymph nodes or the regional lymph nodes (that is, internal mammary chain
lymph nodes or supraclavicular lymph nodes). Distant events are metastases in
distant organs.
Statistical analysis. All bar graphs show sample means±s.e. Single comparisons
were performed using unpaired two-sided Student’s t-test without equal variance.
Multiple comparisons were performed using one-way analysis of variance or two-
way analysis of variance with Dunnett’s or Tukey’s correction for multiple
comparisons, respectively, and were conﬁrmed using non-parametric Mann–
Whitney U-tests. Comparisons between Kaplan–Meier curves were performed
using log-rank test. Statistical signiﬁcance was assumed where Po0.05. A
generalized linear model approach based on beta regression was used to model the
measured density of LYVE-1 immunostaining in primary tumour sections68. Since
the response measurements occur in the interval between 0 and 1, we model the
response measurements Yi by a beta distribution, beta(mi, Fi), where mi is the mean
response and mi(1mi)/Fi is the response variance. In our model both the mean
response and the dispersion parameter depend on a linear combination of the main
treatment effects, with the dispersion parameter capturing mouse heterogeneity.
Model parameters were ﬁtted using maximum likelihood estimation. Results are
reported in Supplementary Table 1.
Association between categorical variables and BB use was evaluated by w2-test,
Fisher exact test or w2-test for trend, as appropriate. Differences in median age and
Ki-67 were tested using the non-parametric median two-sample test. Cumulative
incidences of breast cancer outcomes were compared across different patient
subgroups using the Gray test69. Multivariable Cox proportional hazard models
were applied to adjust the effect of BB for age, tumour stage, peritumoural vascular
invasion, tumour treatment, other antihypertensives, antithrombotics and statins60.
Adjusted hazard ratios with 95% conﬁdence intervals were reported. All analyses
were carried out with SAS software (SAS Institute, Cary, NC) and R software,
version 2.12.2 (ref. 70). All in vitro and in vivo experiments were repeated 2–4
times.
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